Protective effects of BB-10010 treatment on chemotherapy-induced neutropenia in mice

Experimental Hematology

Volumn 27, Issue 2, 1999, Pages 195-202

  Gilmore, Gary L ^a   DePasquale, Darlene K ^a   Shadduck, Richard K ^a  

^a W Pennsylvania Cancer Institute   (United States)

Author keywords

Cell cycle arrest; Chemokines; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUOROURACIL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL CYCLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; LEUKOCYTE COUNT; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOKINES; DRUG ANTAGONISM; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; NEUTROPENIA;

ANIMALIA; ARA;

EID: 0033001213     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(98)00052-6     Document Type: Article

References (21)

1. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V., Rausch G., Smith R., Gradishar W., Yahanda A., Vincent M., Stewart M., Glaspy J. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 325:1991;164.
2. Antman K.S., Griffin J.D., Elias A., Socinski M.A., Ryan L., Cannistra S.A., Oette D., Whitley M., Frei E., Schnipper L.E. Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 319:1988;593.
3. DeVita V.T. Principles of chemotherapy in cancer. DeVita V.T., Hellman S., Rosenberg S.A. Principles and practice of oncology. 2:1985;266 Lippincott, Philadelphia.
4. Broxmeyer H.E. Suppressor cytokines and regulation of myelopoiesis. Am J Ped Hematol Oncol. 14:1992;22.
5. Broxmeyer H.E., Sherry B., Lu L., Cooper S., Oh K.-O., Tekamp-Olsen P., Kwon B.S., Cerami A. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood. 76:1990;1110.
6. Maze R., Sherry B., Kwon B.S., Cerami A., Broxmeyer H.E. Myelo-suppressive effects in vivo of purified recombinant murine macrophage inflammatory protein 1-α J Immunol. 149:1992;1004.
7. Graham G.J., Wright E.G., Hewick R., Wolpe S.D., Wilkie N.M., Donaldson D., Lorimore S., Pragnell I.B. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 344:1990;442.
8. Dunlop D.J., Wright E.J., Lorimore S., Graham G.J., Holyoake T., Kerr D., Wolpe S.D., Pragnell I.B. Demonstration of stem cell inhibition and myeloprotective effects of SCI/MIP-1α in vivo. Blood. 79:1992;2221.
9. Lord B.I., Dexter T.M., Clements J.M., Hunter M.A., Gearing A.J.H. Macrophage inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood. 79:1992;2605.
10. Lord B.I., Marshall E., Woolford L.B., Hunter M.G. BB10010/MIP-1 alpha in vivo maintains haematopoietic recovery following repeated cycles of sublethal irradiation. Br J Cancer. 74:1996;1017.
11. Cook D.N. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leuk Biol. 59:1996;61.
12. Moser M.H., Paukovits W.R. Haemoprotection against cytostatic drugs by stem cell inhibition. Trends Pharm Sci. 12:1991;304.
13. Parker A.N., Pragnell I.B. Inhibitors of haemopoiesis and their potential clinical relevance. Blood Rev. 9:1995;226.
14. Dalmau S.R., Freitas C.S., Savino W. Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines. Leuk Res. 21:1997;93.
15. Mantel C., Kim Y.J., Cooper S., Kwon B., Broxmeyer H.E. Polymerization of murine macrophage inflammatory protein 1-a inactivates its myelo-suppressive effects in vitro. the active form is a monomer Proc Natl Acad Sci U S A. 90:1993;2232.
16. Cooper S., Mantel C., Broxmeyer H.E. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha. Exp Hematol. 22:1994;186.
17. Hunter M.G., Bawden L., Brotherton D., Craig S., Cribbes S., Czaplewski L.G., Dexter T.M., Drummond A.H., Gearing A.H., Heyworth C.H., Lord B.I., McCourt M., Varley P.G., Wood L.M., Edwards R.M., Lewis P.J. BB-10010. an active variant of human macrophage inflammatory protein-1a with improved pharmaceutical properties Blood. 86:1995;4400.
18. Waheed A., Shadduck R.K. Purification and properties of L-cell derived colony-stimulating factor. J Lab Clin Med. 94:1979;180.
19. Wasserman T.H., Phillips T.L., Ross G., Kane L.J. Differential protection against cytotoxic chemotherapy effects on bone marrow CFU-S by WR2721. Cancer Clin Trials. 4:1981;3.
20. Fahey T.J., Tracey K.J., Tekamp-Olsen P., Cousens L.S., Jones W.J., Shires G.T., Cerami A., Sherry B. Macrophage inflammatory protein-1 modulates macrophage function. J Immunol. 148:1992;2764.
21. Vellenga E., van der Vinne B., De Wolf J.T., Halie M.R. Simultaneous expression and regulation of G-CSF and IL-6 mRNA in adherent human monocytes and fibroblasts. Br J Haematol. 78:1991;14.